Given the valuation, end-market exposures, and performance relative to its end-markets, I wasn't too keen on nVent (NVT) back in May of this year. Between weakening industrial end-markets (which I expected), further relative underperformance (which I feared), and the surprising departure of the CFO, as well as management reiterated that it doesn't plan on a large-scale change in its R&D process, the shares are down about 10% from the time of that last article and were down closer to 30% before a decent third quarter and an overall industrial rally lifted the stock.
Relative to